Vai gribat uzzināt, kad nomirsit?
Apskatīt komentārus (0)
25.09.2014
"Zinātnieki paņēma asins paraugus no 17 tūkstošiem sākotnēji veseliem cilvēkiem, kuri tika novēroti turpmākos piecus gadus. Novērojumu laikā 684 cilvēki nomira no dažādām slimībām, tajā skaitā vēža un sirds slimībām. Zinātnieki atklāja, ka visiem mirušajiem bija analoģiski četru biomarķeru līmeņi. Starp tiem albumīna, Alfa-1-skābā glikoproteīna, citrātu un ļoti zema blīvuma lipoproteīnu daļiņu izmērs," rakstīts ziņojumā.
Pētījuma autori norādījuši, ka biomarķeri atspoguļojuši dažādu slimību izraisītus nāves riskus. Tas acīmredzot liecina par organisma vispārēju novājinātību.
Zinātnieki izteikuši cerību, ka nākotnē šo testu izmantos, lai atklātu cilvēkus, kam ir nopietnas slēptās slimības.
Tāpat speciālisti atzīmē, ka pirms viņu iegūtos rezultātus sākt izmantot klīniskajā praksē, nepieciešams veikt papildus pētījumus.
**************************************
Avots: "Would you take the 'death test'? Simple blood test predicts chances of dying within five years" | http://www.independent.co.uk/news/science/would-you-take-the-death-test-simple-blood-test-predicts-chances-of-dying-within-five-years-9155135.html |
Scientists from Finland and Estonia claim said they have now created a death test to predict the chances a person has of dying from a medical condition.
The blood test identifies four biological markers that strongly indicate the risk of dying from any disease within the near future.
A biomarker is a biological molecule, gene or characteristic that may be used to identify a biological state, condition or disease.
Blood samples taken from over 17,000 generally healthy participants were screened for more than a hundred different biomolecules. Their health was monitored for the next five years.
Of the 17,000 participants, 684 died during that period from a range of illnesses, including cancer and heart disease. The scientists found that all of the deceased had similar levels of four biomarkers - albumin; alpha-1-acid glycoprotein; citrate, and a similar size of very-low-density lipoprotein particles.
One in five participants with the highest biomarker scores died within the first year of the study.
Dr Johannes Kettunen, of the Institute for Molecular Medicine Finland, said: What is especially interesting is that these biomarkers reflect the risk for dying from very different types of diseases such as heart disease or cancer. They seem to be signs of a general frailty in the body.
The team are now looking to study whether some kind of connecting factor between these biomarkers can be identified.
We believe that in the future these measures can be used to identify people who appear healthy but in fact have serious underlying illnesses and guide them to proper treatment. More studies are, however, needed before these findings can be implemented in clinical practice.
Estonian researchers initially made the link from a group of 9,842 people and asked Finnish scientists to repeat the experiment on a further 7,503.
Research professor Markus Perola of the Institute for Health and Welfare, Finland told The Telegraph they were not expecting to be able to replicate the findings and were amazed when they were identical.
Prof Perola said: It was a pretty amazing result. First of all we didnt really believe it. It was astonishing that these biomarkers appeared to actually predict mortality independent of disease.
These were all apparently healthy people but to our surprise it appears these biomarkers show an undetected frailty which people did not know they had.
The study was published in the PLOS Medicine journal today.
Atpakaļ